BullFrog AI Shares Surge On Deal With Top Pharma Company For MDD Drug Targets

BullFrog AI Holdings, Inc. (NASDAQ: BFRG) shares surged 17.17% to $1.23 following the announcement of a commercial agreement with a top five global pharmaceutical company to use its bfLEAP platform for identifying drug targets in major depressive disorder (MDD). The agreement aims to accelerate drug discovery and clinical development for MDD and grants exclusive access to a target candidate identified through BullFrog's platform. The collaboration is seen as validation of BullFrog's capabilities and may extend to other areas of the partner's research and development portfolio.